4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator

US9403772B2 · kind B2 · utility

Assignee

• Helsinn Healthcare SA · CH

Inventors

• Luca Fadini · Giubiasco, CH
• Peter Manini · Giubiasco, CH
• Claudio Pietra · Como, IT
• Claudio Giuliano · Como, IT
• Emanuela Lovati · Mendrisio, CH
• Roberta Cannella · Varese, IT
• Alessio Venturini · Varese, IT
• Valentino J. Stella · Lawrence, US

Key dates

• Filing date: Nov 28, 2012
• Grant date: Aug 2, 2016
• Expiry date: Nov 28, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/062
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.